Velocity Clinical Research Germany GmbH

At Velocity Clinical Research Germany GmbH in Leipzig, clinical trial activity is focused on immune system diseases, with a strong emphasis on atopic dermatitis. The studies are designed to assess whether a new treatment approach can better control symptoms and improve skin disease outcomes for people living with moderate-to-severe eczema.

• Evaluating whether rocatinlimab can improve signs and symptoms of atopic dermatitis compared with placebo
• Measuring treatment benefit using established eczema and clinician-assessed outcome tools
• Studying potential benefits in both adults and adolescent patients with moderate-to-severe disease

This research site is contributing to efforts aimed at testing a new therapy for atopic dermatitis and generating clearer evidence on treatment effectiveness in a common inflammatory skin condition.